Strong US sales growth, sustained domestic momentum helps Cipla beat estimates
1 year, 4 months ago

Strong US sales growth, sustained domestic momentum helps Cipla beat estimates

Live Mint  

Cipla's performance in the April-June quarter came better than expectations largely due to strong US sales performance. The analysts feel that contributions from multiple myeloma treatment drug Revlimid generics also contributed to the US sales growth. South Africa Private Market business grew at 13% YoY in local currency terms backed by double digit growth in both prescription and OTC business, said the company. However, the launch of other products and base business growth is likely to remain supportive for US sales growth. Its expanding differentiated pipeline in the US business and strong demand continues within South African private business, with an aim to be the biggest prescription business in South Africa.

Business India Market South Africa Launch Crore Yoy Product Cipla Sales Growth Vohra Us Sales Us Sales Growth  likely  domestic  cipla  sales  growth  strong  beat  business  estimates  yoy  sustained  market  crore  launch  product  helps  momentum

History of this topic

Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.
4 months, 3 weeks ago

Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.

Live Mint  

Stock Market today: Cipla share price that has gained more than 24% year to date is trading near 52 week highs it scaled on Friday. Cipla had reported strong Q1 performance with net profit rising 17% YoY largely helped by improved operating performance as reported Ebitda grew 14% though revenue grew t a slower pace of 7% year-on-year. The same …

Q3 Result Preview: Sun Pharma to lead with highest qoq rise in the US-Jefferies
11 months ago

Q3 Result Preview: Sun Pharma to lead with highest qoq rise in the US-Jefferies

Live Mint  

Q3 Result Preview: The favorable trend seen by Indian Pharma companies on earnings growth during the first half of FY24 may continue during the December quarter too. Analysts at Jefferies India Pvt Ltd expect the current benign US pricing environment to continue and believe most of their coverage firms will clock sequential sales growth in the quarter. Lupin will Dr …

Cipla net soars 43% on growth in India, other key markets
1 year, 1 month ago

Cipla net soars 43% on growth in India, other key markets

Live Mint  

Cipla Ltd posted a 43.4% rise in consolidated net profit for the quarter ended September to ₹1,130.91 crore, against ₹788.90 crore in the corresponding quarter of last year. The drug major’s Q2FY24 revenue increased 14.6% from a year ago from ₹5,828.54 crore to ₹6,678.15 crore, driven by performance in India, the US, and South Africa, it said in an exchange …

Cipla Shares Rally 9% After Q1 Results; Should You Buy, Sell or Hold The Pharma Stock?
1 year, 4 months ago

Cipla Shares Rally 9% After Q1 Results; Should You Buy, Sell or Hold The Pharma Stock?

News 18  

Cipla shares climbed 9 per cent in Thursday’s trade on Thursday after the pharma company reported robust earnings for the first quarter of FY24. Choice Broking said Cipla’s growth story for FY24-25 is premised on scaling up of its US formulations business across a complex portfolio and continued contribution from respiratory and peptide products on the back of new product …

Cipla Q1 net profit rises 45% to ₹996 crore; revenue growth at 18% YoY
1 year, 4 months ago

Cipla Q1 net profit rises 45% to ₹996 crore; revenue growth at 18% YoY

Live Mint  

Cipla reported a 45.1% rise in its consolidated net profit for the quarter ended June 2023 at ₹995.7 crore as compared to ₹696.4 crore in the corresponding quarter of the last year. The company’s US business reported the highest ever revenue of $ 222 million, registering a growth of 43% YoY growth driven by robust momentum in differentiated portfolios. South …

Discover Related